key: cord-0842856-vymu29q2
authors: Mansour, Mayce; Wajnberg, Ania; Altman, Deena R.; Muellers, Kimberly; Stone, Kimberly
title: Demographic Characteristics of Adults with IgG Antibodies to Prior Symptomatic SARS-CoV-2 Infection
date: 2021-01-21
journal: J Gen Intern Med
DOI: 10.1007/s11606-020-06387-9
sha: 7af91a6e56e2ffe0c22aaed7e72e6ad9835d98a2
doc_id: 842856
cord_uid: vymu29q2

nan

While there is growing evidence that a majority of adults exposed to SARS-CoV-2 mount an IgG immune response, 1, 2 little is known about the strength of this response. We conducted antibody testing of adults recovered from SARS-CoV-2 to evaluate potential differences in IgG titer levels based on age, sex, time from symptom onset, and duration of symptoms.

We recruited symptomatic adults recovered from mild SARS-CoV-2 in the New York Tristate area for serum IgG measurement via a REDCap online survey (Vanderbilt University, Tennessee). Respondents were eligible for antibody testing if they had confirmed or high risk suspected symptomatic SARS-CoV-2 infection, defined as having symptoms consistent with SARS-CoV-2 and living someone who was confirmed positive, being told by their physician that they were positive, or working as a healthcare provider. Respondents self-reported date of symptom onset and last date of symptoms; duration of symptoms was calculated from these selfreported dates.

We collected serum IgG antibody titers using a serologic Mount Sinai ELISA test with FDA Emergency Use Authorization (Sn 96%, Sp 100%). 3 In the first 2 weeks of antibody testing, participants were required to be over 7 days from start of symptoms and greater than 3 days asymptomatic; after learning more time was required to mount immunity, we required participants to be over 21 days from symptom onset and greater than 14 days asymptomatic.

One-way ANOVA, Fisher's exact test, and ordinal logistic regression models were used to test whether age, sex, duration of symptoms, or time from symptom start to antibody titer result was associated with titer level. This study was determined to be exempt from Institutional Review Board review.

Between March 24, 2020, and May 15, 2020, we identified 3445 adults with positive antibody titers. Of these adults, 1778 indicated if they had prior positive PCR testing. Twenty-nine percent had titers of ≥ 1:2880, 34.6% had 1:960, 30.6% had 1:320, 4.3% had 1:160 and 1.1% had 1:80. Median time from symptom onset to antibody titer testing was 34 days (range 5-82); median symptom duration was 10 days (range 0-75). In a multivariate ordinal regression model including symptom duration, gender, and age by titer, older age predicted significantly higher odds of higher titer levels with an OR = 1.03 (95% confidence interval: 1.02-1.03). In univariate analyses, age greater than 40 years, male sex, and symptom duration were all associated with increasing IgG titer levels (p < 0.01) ( Table 1) . Ordinal logistic regression models suggested that age greater than 40 years (OR 1.69, CI 1.45-1.98) and male sex (OR 1.22, CI 1.05-1.42) were associated with increased titer levels.

As compared to people with symptoms less than 1 week, participants with symptoms lasting 1 to 2 weeks (OR 1.93, CI 1.63-2.28) or 2 or more weeks (OR 2.67, CI 2.12-3.36) had higher IgG titers. Time from symptom onset was not associated with differences in titer levels ( Fig. 1) .

We found that the majority of individuals with SARS-CoV-2 antibodies had a robust IgG antibody response. While we do not yet know what, if any, SARS-CoV-2 titer level may be associated with protective immunity, 4 understanding variability in immune response for different groups may have important implications for discussions of future immunity, potential risk for reinfection, and possible future vaccine response.

Though others have posited that older groups may be less likely to mount a strong humoral immune response, our data suggests otherwise, with older adults having a response at least as strong as their younger counterparts.

Male sex and duration of symptoms greater than 1 week were associated with higher titer levels. Other studies have shown that older individuals and men are disproportionately affected by SARS-CoV-2, so this may indicate higher viral burden with increased antigen availability in these groups. 5, 6 Similarly, duration of symptoms may be a proxy for severity.

In our cohort, over 95% of recovered patients had mild to moderate COVID-19 that never required emer-gency department or hospitalization. Timing of symptoms was collected by self-report and may have been subject to recall bias. Additionally, we did not collect information regarding participant comorbidities which may confound results. Furthermore, since recruitment was through an online English survey, we may have over-representation here of younger, English-speaking individuals, not reflective of all groups affected by SARS-CoV-2. Figure 1 Adjusted odds ratios of demographic characteristics.

: SARS-CoV-2 Antibody Levels in Adults JGIM

Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

A serological assay to detect SARS-CoV-2 seroconversion in humans

Serology assays to manage COVID-19

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza